Zacks Investment Research upgraded shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) from a sell rating to a hold rating in a research report sent to investors on Monday.

According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “

A number of other equities analysts have also recently issued reports on ATRA. JMP Securities reiterated a buy rating on shares of Atara Biotherapeutics in a report on Saturday, July 9th. Jefferies Group reiterated a buy rating and issued a $25.00 price objective on shares of Atara Biotherapeutics in a report on Tuesday, August 9th. Goldman Sachs Group Inc. cut Atara Biotherapeutics from a neutral rating to a sell rating and cut their price objective for the stock from $23.00 to $16.00 in a report on Thursday, September 15th. Finally, Citigroup Inc. upped their price objective on Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a sell rating in a report on Friday, August 19th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Atara Biotherapeutics currently has a consensus rating of Hold and a consensus target price of $26.14.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Shares of Atara Biotherapeutics (NASDAQ:ATRA) traded down 1.08% during midday trading on Monday, reaching $18.30. The company’s stock had a trading volume of 18,355 shares. The company’s market capitalization is $527.24 million. Atara Biotherapeutics has a 12-month low of $13.31 and a 12-month high of $40.80. The company’s 50-day moving average price is $20.16 and its 200 day moving average price is $20.32.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. On average, equities research analysts forecast that Atara Biotherapeutics will post ($2.85) earnings per share for the current year.

In related news, CEO Isaac E. Ciechanover sold 7,200 shares of the firm’s stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $19.36, for a total transaction of $139,392.00. Following the completion of the transaction, the chief executive officer now owns 229,136 shares of the company’s stock, valued at approximately $4,436,072.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Christopher Haqq sold 1,346 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $22.32, for a total value of $30,042.72. Following the transaction, the insider now directly owns 295,294 shares of the company’s stock, valued at approximately $6,590,962.08. The disclosure for this sale can be found here. 16.10% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC raised its position in Atara Biotherapeutics by 29.9% in the second quarter. FMR LLC now owns 3,125,407 shares of the company’s stock worth $70,353,000 after buying an additional 720,313 shares during the period. Redmile Group LLC raised its position in Atara Biotherapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 2,408,970 shares of the company’s stock worth $54,226,000 after buying an additional 133,205 shares during the period. BlackRock Fund Advisors raised its position in Atara Biotherapeutics by 18.6% in the second quarter. BlackRock Fund Advisors now owns 913,922 shares of the company’s stock worth $20,572,000 after buying an additional 143,242 shares during the period. Bridger Management LLC bought a new position in Atara Biotherapeutics during the first quarter worth $14,072,000. Finally, Vanguard Group Inc. raised its position in Atara Biotherapeutics by 20.3% in the second quarter. Vanguard Group Inc. now owns 679,690 shares of the company’s stock worth $15,300,000 after buying an additional 114,734 shares during the period. 75.50% of the stock is owned by institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.